M&G Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

M&G Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-664	Closed	-$209K	–	445
2023 Q1	$209K	Buy	+664	New	+$199K	﹤0.01%	384
2022 Q4	–	Sell	-742	Closed	-$215	–	466
2022 Q3	$215	Buy	+742	New	+$213K	﹤0.01%	402
2021 Q4	–	Sell	-21,836	Closed	-$3.95K	–	746
2021 Q3	$3.95K	Hold	21,836	–	–	0.01%	444
2021 Q2	$4.41K	Buy	+21,836	New	+$4.57M	0.01%	418
2021 Q1	–	Sell	-911	Closed	-$215	–	484
2020 Q4	$215	Sell	911 -3,026	-77%	-$694K	﹤0.01%	427
2020 Q3	$1.07M	Hold	3,937	–	–	0.01%	289
2020 Q2	$1.14M	Sell	3,937 -2,235	-36%	-$606K	0.01%	292
2020 Q1	$1.47M	Sell	6,172 -259	-4%	-$59.4K	0.02%	264
2019 Q4	$1.41M	Buy	+6,431	New	+$1.3M	0.01%	291

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

M&G Investment Management's VRTX Position: Q2 2023 in Review

M&G Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2023, closing a stake of 664 shares — an estimated $209K sold.

M&G Investment Management first reported a position in VRTX in Q4 2019 and held it in 9 quarters. The position peaked at $1.47M in Q1 2020. 1,285 funds tracked by Wall St. Rank hold VRTX as of Q2 2023.

M&G Investment Management reported no remaining Vertex Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
M&G Investment Management sold 664 Vertex Pharmaceuticals shares in Q2 2023, an estimated $209K.
M&G Investment Management first reported a position in Vertex Pharmaceuticals in Q4 2019 and held it in 9 quarters.
M&G Investment Management's Vertex Pharmaceuticals position peaked at $1.47M in Q1 2020.
1,285 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2023.

Based on M&G Investment Management's 13F filing for Q2 2023, filed 1 Aug 2023.